These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Kazhdan I; Marciniak RA Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201 [TBL] [Abstract][Full Text] [Related]
44. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419 [TBL] [Abstract][Full Text] [Related]
45. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Tang X; Sun YJ; Half E; Kuo MT; Sinicrope F Cancer Res; 2002 Sep; 62(17):4903-8. PubMed ID: 12208739 [TBL] [Abstract][Full Text] [Related]
46. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
47. Translating TRAIL-receptor targeting agents to the clinic. den Hollander MW; Gietema JA; de Jong S; Walenkamp AM; Reyners AK; Oldenhuis CN; de Vries EG Cancer Lett; 2013 May; 332(2):194-201. PubMed ID: 22531313 [TBL] [Abstract][Full Text] [Related]
48. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852 [TBL] [Abstract][Full Text] [Related]
49. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Wenger T; Mattern J; Penzel R; Gassler N; Haas TL; Sprick MR; Walczak H; Krammer PH; Debatin KM; Herr I Cell Death Differ; 2006 Oct; 13(10):1740-51. PubMed ID: 16470224 [TBL] [Abstract][Full Text] [Related]
50. Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance? Plantivaux A; Szegezdi E; Samali A; Egan L Ann N Y Acad Sci; 2009 Aug; 1171():38-49. PubMed ID: 19723036 [TBL] [Abstract][Full Text] [Related]
51. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Matsuzaki H; Schmied BM; Ulrich A; Standop J; Schneider MB; Batra SK; Picha KS; Pour PM Clin Cancer Res; 2001 Feb; 7(2):407-14. PubMed ID: 11234897 [TBL] [Abstract][Full Text] [Related]
53. Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the up-regulation of Bax. Park SJ; Park SH; Kim JO; Kim JH; Park SJ; Hwang JJ; Jin DH; Jeong SY; Lee SJ; Kim JC; Kim I; Cho DH Biochem Biophys Res Commun; 2012 Nov; 428(1):185-90. PubMed ID: 23068102 [TBL] [Abstract][Full Text] [Related]
54. Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL. Holland PM Cancer Lett; 2013 May; 332(2):156-62. PubMed ID: 21220186 [TBL] [Abstract][Full Text] [Related]
55. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. Azijli K; Yuvaraj S; Peppelenbosch MP; Würdinger T; Dekker H; Joore J; van Dijk E; Quax WJ; Peters GJ; de Jong S; Kruyt FA J Cell Sci; 2012 Oct; 125(Pt 19):4651-61. PubMed ID: 22797920 [TBL] [Abstract][Full Text] [Related]
56. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Holoch PA; Griffith TS Eur J Pharmacol; 2009 Dec; 625(1-3):63-72. PubMed ID: 19836385 [TBL] [Abstract][Full Text] [Related]
57. A systems biology approach to overcome TRAIL resistance in cancer treatment. Selvarajoo K Prog Biophys Mol Biol; 2017 Sep; 128():142-154. PubMed ID: 28286052 [TBL] [Abstract][Full Text] [Related]
58. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Dimberg LY; Anderson CK; Camidge R; Behbakht K; Thorburn A; Ford HL Oncogene; 2013 Mar; 32(11):1341-50. PubMed ID: 22580613 [TBL] [Abstract][Full Text] [Related]
59. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data. Gamie Z; Kapriniotis K; Papanikolaou D; Haagensen E; Da Conceicao Ribeiro R; Dalgarno K; Krippner-Heidenreich A; Gerrand C; Tsiridis E; Rankin KS Cancer Lett; 2017 Nov; 409():66-80. PubMed ID: 28888998 [TBL] [Abstract][Full Text] [Related]
60. Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy. de Looff M; de Jong S; Kruyt FAE Front Immunol; 2019; 10():1530. PubMed ID: 31333662 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]